Skip to content

Confocal Laser Endomicroscopy Based Diet in Functional Dyspepsia

Targeted Elimination Diet in FD Patients Following Identification of Trigger Nutrients Using Confocal Laser Endomicroscopy

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05666154
Acronym
CLEFD
Enrollment
65
Registered
2022-12-27
Start date
2021-12-05
Completion date
2025-08-31
Last updated
2024-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Dyspepsia

Brief summary

After a thorough baseline evaluation, functional dyspepsia (FD) patients will be exposed to nutrients while undergoing confocal laser endomicroscopy (CLE). Patients presenting an acute mucosal reaction upon nutrient exposure will be instructed to exclude their respective trigger nutrient or a nutrient without mucosal reaction (=sham diet) from their diet for 4 weeks in a randomized, blinded crossover fashion. The aim of the trial is to assess the symptomatic response to the targeted diet and further elucidate mechanisms underlying the acute mucosal reactions observed in CLE upon nutrient exposure.

Interventions

OTHERReal diet

Diet excluding either trigger nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger)

Diet excluding either sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)

OTHERWheat exclusion diet

Diet excluding wheat in a blinded crossover fashion (CLE negative individuals without identified trigger)

OTHERSoy exclusion diet

Diet excluding soy in a blinded crossover fashion (CLE negative individuals without identified trigger)

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-70 y/o (70 years included) * Male or female subjects * FD (PDS, EPS or overlap) according to Rome IV criteria * Provide written informed consent to participate in the study * Women of child-bearing potential agree to apply a highly effective method of birth control during the entire duration of the trial. Highly effective birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used constantly and correctly such as implants, injectables, combined oral contraceptive method, or some intrauterine devices (IUDs), sexual abstinence, or vasectomized partner. Women of non-childbearing potential may be included if surgically sterile (tubal ligation or hysterectomy) or postmenopausal with at least 2 year without spontaneous menses. * Subjects who are capable to understand the study and the questionnaires, and to comply with the study requirements.

Exclusion criteria

* Pregnant or breastfeeding women * History of major surgery of the gastrointestinal tract (cholecystectomy and uncomplicated appendectomy are allowed) * Symptoms predominantly associated with irritable bowel syndrome or gastro-esophageal reflux disease * IgE-mediated food allergies identified by immunocaps blood tests * Known underlying organic gastrointestinal disease * Current use of NSAIDs, proton-pump inhibitors, systemic histamine-receptor antagonists, mast cell stabilizers, corticosteroids, opioids (need to be stopped at least 2 weeks). Use of antibiotics in the past 6 weeks. * Allergy to Fluorescein or Propofol * Known celiac disease * Following a diet, interfering with the study diet in opinion to the investigators

Design outcomes

Primary

MeasureTime frameDescription
Responder rates in targeted diet vs sham dietAfter 4 weeks of dietary interventionResponse defined by an improvement of minimum 0.5 points on the LPDS scale

Secondary

MeasureTime frameDescription
Baseline duodenal transepithelial electrical resistance between groupsAt baselineDifferences in baseline permeability measures (TEER and flux, measured with ussing chambers on duodenal biopsies) between CLE positive and negative patients and healthy volunteers using Ussing chambers
Baseline duodenal flux of horse-radish peroxidase between groupsAt baselineDifferences in baseline permeability measures (flux, measured with ussing chambers on duodenal biopsies) between CLE positive and negative patients and healthy volunteers using Ussing chambers
Evolution of duodenal flux of horse-radish peroxidase between dietary interventionsBaseline and after 4 weeks of dietDifferences in permeability measures (HRP flux, measured with ussing chambers on duodenal biopsies) between dietary interventions (i.e. verum, sham, wheat and soy) during the dietary interventions using urinary Lactulose/Mannitol/Sucralose ratio
Evolution of duodenal transepithelial electrical resistance between dietary interventionsBaseline and after 4 weeks of dietDifferences in permeability measures (TEER, measured with ussing chambers on duodenal biopsies) between dietary interventions (i.e. verum, sham, wheat and soy) during the dietary interventions using urinary Lactulose/Mannitol/Sucralose ratio
Baseline mucosal immune cell composition between groupsBaselineDifferences in baseline mucosal mast-cell and eosinophil counts between CLE positive and negative patients

Countries

Belgium

Contacts

Primary ContactJolien Schol, MD
jolien.schol@kuleuven.be+3216345663

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026